Novo Nordisk (NYSE:NVO) presented new CagriSema clinical data at EASD 2026, including studies evaluating food-related brain responses, organ fat changes and weight reduction in adults with overweight or obesity.
Merck (NYSE:MRK) reported Phase 2b MK-7240-012 trial results showing investigational tulisokibart achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 in patients with moderate to severe hidradenitis suppurativa.
Eli Lilly (NYSE:LLY) reported Phase 3b ADtouch study results showing EBGLYSS monotherapy met its primary and secondary endpoints in adults and adolescents with hand-and-foot atopic dermatitis.
Sagimet Biosciences (NASDAQ:SGMT) announced 52-week results from license partner Ascletis’ Phase 3 open-label extension trial of denifanstat in moderate to severe acne, with treatment success reaching 56.7% among 240 patients.
AbbVie (NYSE:ABBV) announced Phase 1 results for investigational ABBV-295, reporting adjusted mean weight reductions of up to 9.8% after 12 weeks of weekly dosing in a study involving 60 participants.
Takeda (NYSE:TAK) announced Phase 3 LATITUDE study results for investigational drug zasocitinib (TAK-279), reporting statistically significant improvements compared with deucravacitinib in adults with moderate-to-severe plaque psoriasis.
AbbVie (NYSE:ABBV) announced that it will present 60 dermatology research abstracts, including three late-breaking presentations, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, covering multiple immune-mediated skin diseases.
AbbVie (NYSE:ABBV) reported positive Phase 2 APEX Part B study results for zumilokibart, with all three tested dose regimens achieving the primary endpoint among 346 adults with moderate to severe atopic dermatitis.
Oncolytics Biotech (NASDAQ:ONCY) reported published preclinical findings showing that pelareorep increased markers associated with immune activation in hepatocellular carcinoma (HCC), the most common form of liver cancer.
Cosmos Health (NASDAQ:COSM) reported record second-quarter 2026 revenue exceeding $15 million at its CosmoFarm pharmacy distribution subsidiary.
Propanc Biopharma (NASDAQ:PPCB) reported fiscal 2026 financial results and provided an update on development plans for PRP, its investigational cancer therapy candidate.
Iovance Biotherapeutics (NASDAQ:IOVA) raised its full-year 2026 revenue guidance following stronger-than-expected demand for its commercial products, Amtagvi and Proleukin.
